ELISA/assay

Epidermal Growth Factor (EGF)

MBS590002

96 Wells

580 USD

ELISA Kit

Epidermal Growth Factor (EGF)

Epidermal Growth Factor

epidermal growth factor, partial; Pro-epidermal growth factor; pro-epidermal growth factor; beta-urogastrone; epidermal growth factor; Epidermal growth factorAlternative name(s):Urogastrone

EGF

EGF; EGF; URG; HOMG4

EGF_HUMAN

53

This sandwich ELISA recognises both natural and recombinant human EGF. This kit exhibits no detectable cross-reactivity with human; IL-8, IL-1beta, MCAF, TGF-alpha, TGF-beta, SAA, MCP-3, TNF-alpha, RANTES, EPO, M-CSF, GM-CSF, and FGF.

Intended Uses: This Human EGF ELISA kit is to be used for the in vitro quantitative determination of human epidermal growth factor (EGF) concentrations in serum, plasma, cell culture supernatant, urine, and other biological fluids. This kit is intended FOR LABORATORY RESEARCH USE ONLY and is not for use in diagnostic or therapeutic procedures.

Sensitivity: The minimum detectable dose of EGF was determined by adding two standard deviations to the mean optical density value of the 20 zero standard replicates and calculating the corresponding concentration from the standard curve. The minimum detectable dose using a standard curve generated with Calibrator Diluent I is 20 pg/mL and using Calibrator Diluent II is 15 pg/mL. Intra-assay Precision: To determine within-run precision, three different samples of known concentration were assayed by using 17-20 replicates in 1 assay. Inter-assay Precision: To determine between-run precision, three different samples of known concentration were assayed by using replicates on 20 different assays.

ELISA Kits for Human Cytokines and Receptors

Principle of the assay: This EGF enzyme-linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been precoated with a monoclonal specific for EGF. Standards or samples are then added to the appropriate microtiter plate wells and incubated. EGF, if present, will bind and become immobilized by the antibody pre-coated on the wells. The microtiter plate wells are thoroughly washed to remove unbound EGF and other components of sample. In order to quantitate the amount of EGF present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated monoclonal antibody specific for EGF is added to each well to "sandwich" the EGF immobilized during the first incubation. The microtiter plate then undergoes a second incubation. The wells are thoroughly washed to remove all unbound HRP-conjugated antibodies and a TMB (3,3'5,5' tetramethyl-benzidine) substrate solution is added to each well. The enzyme (HRP) and substrate are allowed to react over a short incubation period. Only those wells that contain EGF and enzyme-conjugated antibody will exhibit a change in colour. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the colour change is measured spectrophotometrically at a wavelength of 450 nm +/- 2 nm. In order to measure the concentration of EGF in the samples, this kit contains two calibration diluents (Calibrator Diluent I for serum/plasma testing and Calibrator Diluent II for cell culture supernatant/ urine testing). According to the testing system, the provided standard is diluted (2-fold) with the appropriate Calibrator Diluent and assayed at the same time as the samples. This allows the operator to produce a standard curve of Optical Density (O.D.) versus EGF concentration (pg/mL). The concentration of EGF in the samples is then determined by comparing the O.D. of the samples to the standard curve.

46242544

AAS83395.1

129,746 Da

Adaptive Immune System Pathway 366160!!Arf6 Signaling Events Pathway 138034!!Bladder Cancer Pathway 83115!!Bladder Cancer Pathway 527!!Ceramide Signaling Pathway 138023!!Choline Metabolism In Cancer Pathway 1059539!!Choline Metabolism In Cancer Pathway 1084232!!Constitutive PI3K/AKT Signaling In Cancer Pathway 685535!!Constitutive Signaling By EGFRvIII Pathway 1127578!!Constitutive Signaling By Ligand-Responsive EGFR Cancer Variants Pathway 530769

This gene encodes a member of the epidermal growth factor superfamily. The encoded protein is synthesized as a large precursor molecule that is proteolytically cleaved to generate the 53-amino acid epidermal growth factor peptide. This protein acts a potent mitogenic factor that plays an important role in the growth, proliferation and differentiation of numerous cell types. This protein acts by binding the high affinity cell surface receptor, epidermal growth factor receptor. Defects in this gene are the cause of hypomagnesemia type 4. Dysregulation of this gene has been associated with the growth and progression of certain cancers. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2010]

96 Wells

580 USD